Search results for " non-Hodgkin"

showing 7 items of 87 documents

Facteurs épidémiologiques influençant la survie dans le lymphome à cellules du manteau

2017

Mantle Cell Lymphoma (MCL) is a recently defined entity, typically characterised by the genetic translocation t(11 ;14)(q13 ;q32) and counting for 2 - 10% of all non-Hodgkin Lymphomas. With a median survival between 3 and 5 years after diagnosis, MCL is an agressive disease and despite the recent therapeutic advances little in know about its prognostic factors. Some studies had investigated clinicopathological features and new treatment strategies, but there is a lack of knowledge regarding the impact of lifestyle and environnemental factors on outcome of MCL patients. From 2008 to 2012, the LYSA Group conducted in France two prospective multi center clinical trials on MCL : LM manteau 2010…

[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologySurvivalMantle Cell LymphomaNon-Hodgkin LymphomaPopulation-Based studyPrognostic factorsLymphome à Cellules du ManteauClinical TrialEssai CliniqueSurvieFacteurs pronosticsEtude en population généraleLymphome non-Hodgkinien[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas,

2014

Histone deacetylases (HDAC) extensively contribute to the c-Myc oncogenic program, pointing to their inhibition as an effective strategy against c-Myc-overexpressing cancers. We, thus, studied the therapeutic activity of the new-generation pan-HDAC inhibitor ITF2357 (Givinostat®) against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas (B-NHLs). ITF2357 anti-proliferative and pro-apoptotic effects were analyzed in B-NHL cell lines with c-Myc translocations (Namalwa, Raji and DOHH-2), stabilizing mutations (Raji) or post-transcriptional alterations (SU-DHL-4) in relationship to c-Myc modulation. ITF2357 significantly delayed the in vitro growth of all B-NHL cell lines by inducing G1 c…

c-MycmicroRNAnon-Hodgkin lymphomac-Myc; histone deacetylase inhibitors; microRNA; non-Hodgkin lymphomahistone deacetylase inhibitor
researchProduct

Computer-assisted interpretation of flow cytometry data in hematology.

1996

A computer program has been developed for computer-assisted diagnosis (including subclassification) of flow cytometry data of acute leukaemias and non-Hodgkin lymphomas by means of artificial intelligence. The knowledge base for the system has been formulatedas semantic networks that describe physiological hematopoiesisas well as the pathological situation (eg., aberrant antigen expression) of hematological disorders. The semantic networks reflect the hierarchy of cells and their occurrence in diseases, the normal and pathological antigen expression patterns of cells, cell maturation, and the frequency of cell populations in normal blood and bone marrow. Using these semantic networks, the d…

medicine.medical_specialtyCellBiophysicsExpert SystemsDiseaseCell MaturationPathology and Forensic MedicineFlow cytometryEndocrinologyAntigenInternal medicineMedicineHumansDiagnosis Computer-AssistedPathologicalHematologyLeukemiamedicine.diagnostic_testbusiness.industryLymphoma Non-HodgkinReproducibility of ResultsCell BiologyHematologyFlow Cytometrymedicine.anatomical_structureData Interpretation StatisticalImmunologyAcute DiseaseBone marrowbusinessCytometry
researchProduct

Whole body magnetic resonance in indolent lymphomas under watchful waiting: The time is now.

2017

The indolent non-Hodgkin lymphomas (i-NHLs) are characterised by ‘indolent’ clinical behaviour with slow growth and prolonged natural history. The watchful waiting (WW) strategy is a frequently employed treatment option in these patients. This implies a strict monitoring by imaging examinations, including 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) and CT. A major concern is radiation exposure due to regularly monitoring by conventional imaging procedures. Several studies have demonstrated the reliability of whole-body magnetic resonance imaging (WB-MRI) for lymphoma staging. WB-MRI could be useful for active surveillance in i-NHLs providing the …

medicine.medical_specialtyLymphomamedicine.medical_treatmentWhole body imaging030218 nuclear medicine & medical imaging03 medical and health sciencesMagnetic resonance imaging0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesmedicinemedia_common.cataloged_instanceHumansRadiology Nuclear Medicine and imagingWhole Body ImagingEuropean unionWatchful WaitingNeuroradiologymedia_commonmedicine.diagnostic_testbusiness.industryLymphoma Non-HodgkinReproducibility of ResultsMagnetic resonance imagingInterventional radiologyGeneral Medicinemedicine.diseaseLymphomaRadiation therapyDiffusion Magnetic Resonance Imaging030220 oncology & carcinogenesisDisease ProgressionIonising radiationRadiologybusinessWatchful waitingEuropean radiology
researchProduct

Primary extranodal non-Hodgkin lymphomas of the uterus and the breast: report of three cases

1995

The authors describe one case of a rare primitive non-Hodgkin lymphoma of the uterus, and two cases of primary non-Hodgkin lymphoma of the breast. Histologically, the uterine lymphoma, although clinically confined to the uterus, was a diffuse large cell lymphoma, group G according to the Working formulation for Clinical Usage. The two cases of breast lymphoma were a centrocytic-centroblastic and a lymphoplasmocytoid non-Hodgkin lymphoma, respectively. All cases were initally treated with radical surgery plus radiotherapy, but the first patient showed an early recurrence at distant sites, which required systemic cytotoxic chemotherapy. The patient with uterine non-Hodgkin lymphoma received a…

medicine.medical_specialtyPathologyWorking Formulationmedicine.medical_treatmentMammary glandUterusBreast NeoplasmsCHOPimmune system diseaseshemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineRadical surgeryChemotherapybusiness.industryLymphoma Non-HodgkinGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyLymphomaRadiation therapymedicine.anatomical_structureOncologyUterine NeoplasmsFemaleSurgeryLymphoma Large B-Cell DiffuseRadiologybusinessEuropean Journal of Surgical Oncology (EJSO)
researchProduct

Prurigo nodularis as index symptom of (non-Hodgkin) lymphoma: ultrasound as a helpful diagnostic tool in dermatological disorders of unknown origin

2014

medicine.medical_specialtybusiness.industryLymphoma Non-HodgkinUltrasoundDermatologymedicine.diseaseDermatologyHumansMedicineHodgkin lymphomaFemalePrurigoDermatological disordersbusinessPrurigo nodularisAgedUltrasonographyInternational Journal of Dermatology
researchProduct

B-Cell Receptor Signaling Is Thought to Be a Bridge between Primary Sjogren Syndrome and Diffuse Large B-Cell Lymphoma

2023

Primary Sjogren syndrome (pSS) is the second most common autoimmune disorder worldwide, which, in the worst scenario, progresses to Non-Hodgkin Lymphoma (NHL). Despite extensive studies, there is still a lack of knowledge about developing pSS for NHL. This study focused on cells’ signaling in pSS progression to the NHL type of diffuse large B-cell lymphoma (DLBCL). Using bulk RNA and single cell analysis, we found five novel pathologic-independent clusters in DLBCL based on cells’ signaling. B-cell receptor (BCR) signaling was identified as the only enriched signal in DLBCL and pSS peripheral naive B-cells or salivary gland-infiltrated cells. The evaluation of the genes in association with …

non-hodgkins lymphomaprimary Sjogren syndrome; non-hodgkins lymphoma; DLBCL; cell signaling; BCROrganic ChemistryGeneral MedicineBCRprimary Sjogren syndromeCatalysisComputer Science ApplicationsInorganic ChemistryDLBCLcell signalingPhysical and Theoretical ChemistryMolecular BiologySpectroscopyInternational Journal of Molecular Sciences; Volume 24; Issue 9; Pages: 8385
researchProduct